Related Experiment Video
Updated: Aug 30, 2025
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.3K
A genetic model for central chondrosarcoma evolution correlates with patient outcome
William Cross1, Iben Lyskjær1,2, Tom Lesluyes3
1Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.
Genome Medicine
|August 30, 2022
Summary
Genomic testing for IDH1, IDH2, and TERT mutations in central conventional chondrosarcoma improves prognostic accuracy. Different mutation profiles correlate with distinct clinical outcomes and patient demographics, aiding in prognostication.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Central conventional chondrosarcoma (CS) is a common adult bone cancer with limited treatment and challenging prognoses.
- IDH1, IDH2, and TERT mutations are found in CS, but their impact on clinical outcomes is not fully understood.
Purpose of the Study:
- To determine if incorporating genomic data, specifically IDH1, IDH2, and TERT mutations, can enhance prognostic accuracy for CS.
- To investigate the correlation between specific genetic mutations and clinical features or patient outcomes.
Main Methods:
- Analysis of 356 CS samples using digital droplet PCR and whole genome sequencing to profile IDH1, IDH2, and TERT mutations.
- Examination of complex genetic events, methylation array data, and correlation with clinical data and patient outcomes.
Main Results:
- IDH2-mutant CS tumors are associated with older patients and higher grade disease; TERT mutations in this group do not affect survival.
- TERT mutations in IDH1-mutant CS are rarer but linked to poorer outcomes.
- IDH wild-type tumors show distinct genetic features like haploidization, occur in younger patients, and have a lower risk of dedifferentiation.
Conclusions:
- Distinct genetic pathways and outcomes exist for IDH1/IDH2-mutant and IDH wild-type CS, particularly concerning TERT mutations.
- Diagnostic testing for IDH1, IDH2, and TERT mutations can significantly improve clinical monitoring and prognostication for CS patients.
